Yuka Fujita

Dr. Yuka Fujita


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2020 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
YKYosuke Kawashima
Yosuke Kawashima
THToshiyuki Harada
Toshiyuki Harada
YFYuka Fujita
Yuka Fujita
TNTaku Nakagawa
Taku Nakagawa
KWKana Watanabe
Kana Watanabe
SSShunichi Sugawara
Shunichi Sugawara

23 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
YMYu Miura
Yu Miura
HIHisao Imai
Hisao Imai
SESatoshi Endo
Satoshi Endo
KHKosuke Hashimoto
Kosuke Hashimoto
OYOu Yamaguchi
Ou Yamaguchi
KKKyoichi Kaira
Kyoichi Kaira
Older patients with unresectable locally advanced non-small cell lung cancer (NSCLC) frequently receive concurrent chemoradiotherapy (CCRT) with daily low-dose carboplatin; however, real-world data on its efficacy, safety, and prognostic factors remain limited. We aimed to retrospectively evaluate the clinical outcomes of this regimen and examined whether systemic inflammation-based indices predict prognosis in this setting. We reviewed 52 consecutive patients with locally advanced NSCLC treated with first-line CCRT using daily low-dose carboplatin at three Japanese institutions between April 2007 and December 2019. The median progression-free survival (PFS) and overall survival (OS) were 11.5 and 40.1 months, respectively. Twenty patients received durvalumab as maintenance therapy. In the overall cohort, multivariate analysis identified the Glasgow Prognostic Score (GPS) as an independent predictor of PFS. A GPS of 0–1 was also associated with a significantly longer OS in univariate analysis. CCRT with daily low-dose carboplatin provided durable disease control with acceptable toxicity in older patients with unresectable stage II/III NSCLC. The GPS appears to be a simple marker for PFS in this population and may aid in pretreatment risk stratification alongside histology and consolidation strategies.